D. Vaudry, A. Falluel-morel, S. Bourgault, M. Basille, D. Burel et al., Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery, Pharmacological Reviews, vol.61, issue.3, pp.283-357, 2009.
DOI : 10.1124/pr.109.001370

A. Harmar, J. Fahrenkrug, I. Gozes, M. Laburthe, V. May et al., Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1, British Journal of Pharmacology, vol.123, issue.1, pp.4-17, 2012.
DOI : 10.1111/j.1476-5381.2012.01871.x

M. Delgado, D. Pozo, and D. Ganea, The Significance of Vasoactive Intestinal Peptide in Immunomodulation, Pharmacological Reviews, vol.56, issue.2, pp.249-90, 2004.
DOI : 10.1124/pr.56.2.7

M. Delgado, E. Munoz-elias, Y. Kan, I. Gozes, M. Fridkin et al., Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor ?? Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-Jun, Journal of Biological Chemistry, vol.273, issue.47, pp.31427-31463, 1998.
DOI : 10.1074/jbc.273.47.31427

M. Delgado, C. Martinez, M. Johnson, R. Gomariz, and D. Ganea, Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes, Journal of Neuroimmunology, vol.68, issue.1-2, pp.27-38, 1996.
DOI : 10.1016/0165-5728(96)00063-X

M. Delgado, A. Reduta, V. Sharma, and D. Ganea, VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4+ T cells, Journal of Leukocyte Biology, vol.75, issue.6, pp.1122-1152, 2004.
DOI : 10.1189/jlb.1203626

D. Pozo, M. Delgado, C. Martinez, R. Gomariz, J. Guerrero et al., Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages1David Pozo and Mario Delgado contributed equally to this work.1, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1359, issue.3, pp.250-62, 1997.
DOI : 10.1016/S0167-4889(97)00104-3

M. Delgado, D. Pozo, C. Martinez, J. Leceta, J. Calvo et al., Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies, J Immunol, vol.162, pp.2358-67, 1999.

C. Martinez, M. Delgado, D. Pozo, J. Leceta, J. Calvo et al., Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages, J Leukoc Biol, vol.63, pp.591-601, 1998.

M. Delgado, E. Munoz-elias, R. Gomariz, and D. Ganea, VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFN?? synthesis by T cells, Journal of Neuroimmunology, vol.96, issue.2, pp.167-81, 1999.
DOI : 10.1016/S0165-5728(99)00023-5

A. Chorny, E. Gonzalez-rey, N. Varela, G. Robledo, and M. Delgado, Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions, Regulatory Peptides, vol.137, issue.1-2, pp.67-74, 2006.
DOI : 10.1016/j.regpep.2006.04.021

M. Delgado, VIP: a very important peptide in T helper differentiation, Trends in Immunology, vol.24, issue.5, pp.221-225, 2003.
DOI : 10.1016/S1471-4906(03)00069-3

J. Voice, G. Dorsam, R. Chan, C. Grinninger, Y. Kong et al., Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide, Regulatory Peptides, vol.109, issue.1-3, pp.199-208, 2002.
DOI : 10.1016/S0167-0115(02)00182-9

M. Delgado, J. Leceta, R. Gomariz, and D. Ganea, Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression, J Immunol, vol.163, pp.3629-3664, 1999.

M. Delgado, J. Leceta, W. Sun, R. Gomariz, and D. Ganea, VIP and PACAP Induce Shift to a Th2 Response by Upregulating B7.2 Expression, Annals of the New York Academy of Sciences, vol.93, issue.1, pp.68-78, 2000.
DOI : 10.1111/j.1749-6632.2000.tb06952.x

M. Delgado, E. Gonzalez-rey, and D. Ganea, VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells, The FASEB Journal, vol.18, pp.1453-1458, 2004.
DOI : 10.1096/fj.04-1548fje

D. Fabricius, O. Dorisio, M. Blackwell, S. Jahrsdorfer, and B. , Human Plasmacytoid Dendritic Cell Function: Inhibition of IFN-?? Secretion and Modulation of Immune Phenotype by Vasoactive Intestinal Peptide, The Journal of Immunology, vol.177, issue.9, pp.5920-5927, 2006.
DOI : 10.4049/jimmunol.177.9.5920

V. Sharma, M. Delgado, and D. Ganea, VIP Protects Th2 Cells by Downregulating Granzyme B Expression, Annals of the New York Academy of Sciences, vol.1070, issue.1, pp.540-544, 2006.
DOI : 10.1196/annals.1317.077

V. Sharma, M. Delgado, and D. Ganea, Granzyme B, a New Player in Activation-Induced Cell Death, Is Down-Regulated by Vasoactive Intestinal Peptide in Th2 but Not Th1 Effectors, The Journal of Immunology, vol.176, issue.1, pp.97-110, 2006.
DOI : 10.4049/jimmunol.176.1.97

M. Delgado, J. Leceta, and D. Ganea, Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells, The FASEB Journal, vol.16, pp.1844-1850, 2002.
DOI : 10.1096/fj.02-0248fje

M. Delgado, A. Chorny, E. Gonzalez-rey, and D. Ganea, Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo, Journal of Leukocyte Biology, vol.78, issue.6, pp.1327-1365, 2005.
DOI : 10.1189/jlb.0605299

E. Gonzalez-rey, A. Chorny, A. Fernandez-martin, D. Ganea, and M. Delgado, Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells, Blood, vol.107, issue.9, pp.3632-3640, 2006.
DOI : 10.1182/blood-2005-11-4497

E. Gonzalez-rey and M. Delgado, Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis, Trends in Molecular Medicine, vol.13, issue.6, pp.241-51, 2007.
DOI : 10.1016/j.molmed.2007.04.003

E. Gonzalez-rey and M. Delgado, Therapeutic Treatment of Experimental Colitis With Regulatory Dendritic Cells Generated With Vasoactive Intestinal Peptide, Gastroenterology, vol.131, issue.6, pp.1799-811, 2006.
DOI : 10.1053/j.gastro.2006.10.023

E. Gonzalez-rey, A. Fernandez-martin, A. Chorny, and M. Delgado, Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis, Arthritis & Rheumatism, vol.201, issue.3, pp.864-76, 2006.
DOI : 10.1002/art.21652

A. Fernandez-martin, E. Gonzalez-rey, A. Chorny, D. Ganea, and M. Delgado, Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis, European Journal of Immunology, vol.100, issue.2, pp.318-344, 2006.
DOI : 10.1002/eji.200535430

M. Delgado, C. Abad, C. Martinez, J. Leceta, and R. Gomariz, Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease, Nature Medicine, vol.7, issue.5, pp.563-571, 2001.
DOI : 10.1038/87887

C. Abad, C. Martinez, M. Juarranz, A. Arranz, J. Leceta et al., Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease, Gastroenterology, vol.124, issue.4, pp.961-71, 2003.
DOI : 10.1053/gast.2003.50141

E. Gonzalez-rey, A. Fernandez-martin, A. Chorny, J. Martin, D. Pozo et al., Therapeutic Effect of Vasoactive Intestinal Peptide on Experimental Autoimmune Encephalomyelitis, The American Journal of Pathology, vol.168, issue.4, pp.1179-88, 2006.
DOI : 10.2353/ajpath.2006.051081

M. Rangachari and V. Kuchroo, Using EAE to better understand principles of immune function and autoimmune pathology, Journal of Autoimmunity, vol.45, pp.31-40, 2013.
DOI : 10.1016/j.jaut.2013.06.008

B. Hemmer, M. Kerschensteiner, and T. Korn, Role of the innate and adaptive immune responses in the course of multiple sclerosis, The Lancet Neurology, vol.14, issue.4, pp.406-425, 2015.
DOI : 10.1016/S1474-4422(14)70305-9

Y. Tan, C. Abad, Y. Wang, R. Lopez, and J. Waschek, VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses, Brain, Behavior, and Immunity, vol.44, pp.167-75, 2015.
DOI : 10.1016/j.bbi.2014.09.020

C. Abad, Y. Tan, R. Lopez, H. Nobuta, H. Dong et al., Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis, Proceedings of the National Academy of Sciences, vol.107, issue.45, pp.19555-60, 2010.
DOI : 10.1073/pnas.1007622107

C. Abad, Y. Tan, G. Cheung-lau, H. Nobuta, and J. Waschek, VIP Deficient Mice Exhibit Resistance to Lipopolysaccharide Induced Endotoxemia with an Intrinsic Defect in Proinflammatory Cellular Responses, PLoS ONE, vol.30, issue.5, p.36922, 2012.
DOI : 10.1371/journal.pone.0036922.g005

C. Abad, G. Cheung-lau, A. Coute-monvoisin, and J. Waschek, Vasoactive Intestinal Peptide-Deficient Mice Exhibit Reduced Pathology in Trinitrobenzene Sulfonic Acid-Induced Colitis, Neuroimmunomodulation, vol.22, issue.3, pp.203-215, 2015.
DOI : 10.1159/000364912

D. Fabricius, B. Karacay, D. Shutt, W. Leverich, B. Schafer et al., Characterization of Intestinal and Pancreatic Dysfunction in VPAC1-Null Mutant Mouse, Pancreas, vol.40, issue.6, pp.861-71, 2011.
DOI : 10.1097/MPA.0b013e318214c783

Y. Tan, C. Abad, R. Lopez, H. Dong, S. Liu et al., Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis, Proceedings of the National Academy of Sciences, vol.106, issue.6, pp.2012-2019, 2009.
DOI : 10.1073/pnas.0812257106

P. Gourlet, D. Neef, P. Cnudde, J. Waelbroeck, M. Robberecht et al., In Vitro Properties of a High Affinity Selective Antagonist of the VIP1 Receptor, Peptides, vol.18, issue.10, pp.1555-60, 1997.
DOI : 10.1016/S0196-9781(97)00230-1

K. Livak and T. Schmittgen, Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2???????CT Method, Methods, vol.25, issue.4, pp.402-410, 2001.
DOI : 10.1006/meth.2001.1262

P. Kivisakk, J. Imitola, S. Rasmussen, W. Elyaman, B. Zhu et al., Localizing central nervous system immune surveillance: Meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis, Annals of Neurology, vol.14, issue.pt 6, pp.457-69, 2009.
DOI : 10.1002/ana.21379

D. Huang, J. Wang, P. Kivisakk, B. Rollins, and R. Ransohoff, Absence of Monocyte Chemoattractant Protein 1 in Mice Leads to Decreased Local Macrophage Recruitment and Antigen-Specific T Helper Cell Type 1 Immune Response in Experimental Autoimmune Encephalomyelitis, The Journal of Experimental Medicine, vol.161, issue.6, pp.713-739, 2001.
DOI : 10.1084/jem.184.2.771

B. Fife, G. Huffnagle, W. Kuziel, and W. Karpus, Cc Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune Encephalomyelitis, The Journal of Experimental Medicine, vol.7, issue.6, pp.899-905, 2000.
DOI : 10.1038/385640a0

M. Delgado, R. Gomariz, C. Martinez, C. Abad, and J. Leceta, Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock, European Journal of Immunology, vol.163, issue.11, pp.3236-3282, 2000.
DOI : 10.1002/1521-4141(200011)30:11<3236::AID-IMMU3236>3.0.CO;2-L

M. Lara-marquez, O. Dorisio, M. , O. Dorisio, T. Shah et al., Selective Gene Expression and Activation-Dependent Regulation of Vasoactive Intestinal Peptide Receptor Type 1 and Type 2 in Human T Cells, The Journal of Immunology, vol.166, issue.4
DOI : 10.4049/jimmunol.166.4.2522

A. Storka, B. Burian, G. Fuhrlinger, C. B. Sun, T. Crevenna et al., VPAC1 receptor expression in peripheral blood mononuclear cells in a human endotoxemia model, Journal of Translational Medicine, vol.11, issue.1, p.117, 2013.
DOI : 10.1172/JCI110404

R. Hermann, T. Van-der-steen, E. Vomhof-dekrey, S. Badrani, S. Wanjara et al., Characterization and use of a rabbit-anti-mouse VPAC1 antibody by flow cytometry, Journal of Immunological Methods, vol.376, issue.1-2, pp.20-31, 2012.
DOI : 10.1016/j.jim.2011.10.009

E. Vomhof-dekrey, R. Hermann, M. Palmer, K. Benton, A. Sandy et al., TCR signaling and environment affect vasoactive intestinal peptide receptor-1 (VPAC-1) expression in primary mouse CD4 T cells, Brain, Behavior, and Immunity, vol.22, issue.7, pp.1032-1072, 2008.
DOI : 10.1016/j.bbi.2008.04.005

E. Vomhof-dekrey and G. Dorsam, Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells, Brain, Behavior, and Immunity, vol.22, issue.7, pp.1024-1055, 2008.
DOI : 10.1016/j.bbi.2008.04.006

E. Cocco, F. Paladini, G. Macino, V. Fulci, M. Fiorillo et al., The Expression of Vasoactive Intestinal Peptide Receptor 1 Is Negatively Modulated by MicroRNA 525-5p, PLoS ONE, vol.16, issue.8, p.12067, 2010.
DOI : 10.1371/journal.pone.0012067.g008
URL : https://hal.archives-ouvertes.fr/hal-00543355

J. Herrera, E. Gonzalez-rey, R. Fernandez-montesinos, F. Quintana, R. Najmanovich et al., Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages, Journal of Cellular and Molecular Medicine, vol.180, issue.9b, pp.3209-3226, 2009.
DOI : 10.1111/j.1582-4934.2008.00662.x

N. Kawakami, I. Bartholomaus, M. Pesic, and M. Mues, An autoimmunity odyssey: how autoreactive T cells infiltrate into the CNS, Immunological Reviews, vol.479, issue.1, pp.140-55, 2012.
DOI : 10.1111/j.1600-065X.2012.01133.x

J. Johnston, D. Taub, A. Lloyd, K. Conlon, J. Oppenheim et al., Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide, J Immunol, vol.153, pp.1762-1770, 1994.

M. Xia, D. Leppert, S. Hauser, S. Sreedharan, P. Nelson et al., Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane

P. Schratzberger, A. Geiseler, S. Dunzendorfer, N. Reinisch, C. Kahler et al., Similar involvement of VIP receptor type I and type II in lymphocyte chemotaxis, Journal of Neuroimmunology, vol.87, issue.1-2, pp.73-81, 1998.
DOI : 10.1016/S0165-5728(98)00043-5

S. Dorsam, E. Vomhof-dekrey, R. Hermann, J. Haring, T. Van-der-steen et al., Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells, Molecular Immunology, vol.47, issue.6, pp.1181-94, 2010.
DOI : 10.1016/j.molimm.2010.01.003

J. Yang, Q. Shi, T. Song, G. Feng, W. Zang et al., Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro, Peptides, vol.42, pp.105-116, 2013.
DOI : 10.1016/j.peptides.2013.01.007

A. Castorina, S. Giunta, V. Mazzone, V. Cardile, D. Agata et al., Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells, Peptides, vol.31, issue.12, pp.2276-83, 2010.
DOI : 10.1016/j.peptides.2010.08.013

K. Joo, Y. Chung, M. Kim, R. Nam, B. Lee et al., Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain, The Journal of Comparative Neurology, vol.7, issue.4, pp.388-413, 2004.
DOI : 10.1002/cne.20231

M. Delgado, Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia, Biochemical and Biophysical Research Communications, vol.293, issue.2, pp.771-777, 2002.
DOI : 10.1016/S0006-291X(02)00283-8

Y. Arima, M. Harada, D. Kamimura, J. Park, F. Kawano et al., Regional Neural Activation Defines a Gateway for Autoreactive T Cells to Cross the Blood-Brain Barrier, Cell, vol.148, issue.3, pp.447-57, 2012.
DOI : 10.1016/j.cell.2012.01.022

C. Martinez, M. Delgado, D. Pozo, J. Leceta, J. Calvo et al., VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies1The first two authors have contributed equally to the present work.1, Journal of Neuroimmunology, vol.85, issue.2, pp.155-67, 1998.
DOI : 10.1016/S0165-5728(98)00018-6

A. Reboldi, C. Coisne, D. Baumjohann, F. Benvenuto, D. Bottinelli et al., C-C chemokine receptor 6???regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE, Nature Immunology, vol.181, issue.5, pp.514-537, 2009.
DOI : 10.1002/glia.1101

B. Kis, C. Abraham, M. Deli, H. Kobayashi, M. Niwa et al., Adrenomedullin, an Autocrine Mediator of Blood-Brain Barrier Function, Hypertension Research, vol.26, issue.Suppl, pp.61-70, 2003.
DOI : 10.1291/hypres.26.S61

B. Kis, L. Chen, Y. Ueta, and D. Busija, Autocrine peptide mediators of cerebral endothelial cells and their role in the regulation of blood???brain barrier, Peptides, vol.27, issue.1, pp.211-233, 2006.
DOI : 10.1016/j.peptides.2005.07.009

D. Staines, E. Brenu, and S. Marshall-gradisnik, Postulated Role of Vasoactive Neuropeptide-Related Immunopathology of the Blood Brain Barrier and Virchow-Robin Spaces in the Aetiology of Neurological-Related Conditions, Mediators of Inflammation, vol.19, issue.1, p.792428, 2008.
DOI : 10.1016/j.brainres.2007.12.023

J. Hansen, J. Sitarz, S. Birk, A. Rahmann, P. Oturai et al., Vasoactive Intestinal Polypeptide Evokes Only a Minimal Headache in Healthy Volunteers, Cephalalgia, vol.22, issue.8758, pp.992-1003, 2006.
DOI : 10.1002/cne.20688

H. Schytz, S. Birk, T. Wienecke, C. Kruuse, J. Olesen et al., PACAP38 induces migraine-like attacks in patients with migraine without aura, Brain, vol.132, issue.1, pp.16-25, 2009.
DOI : 10.1093/brain/awn307

M. Yadav, M. Huang, and E. Goetzl, VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis, Cellular Immunology, vol.267, issue.2, pp.124-156, 2011.
DOI : 10.1016/j.cellimm.2011.01.001

D. Maimone, C. Cioni, S. Rosa, G. Macchia, F. Aloisi et al., Norepinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: Synergism with IL-1?? and TNF??, Journal of Neuroimmunology, vol.47, issue.1, pp.73-81, 1993.
DOI : 10.1016/0165-5728(93)90286-8

P. Rameshwar, P. Gascon, H. Oh, T. Denny, G. Zhu et al., Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor, Experimental Hematology, vol.30, issue.9, pp.1001-1010, 2002.
DOI : 10.1016/S0301-472X(02)00875-5

L. Souza-moreira, M. Morell, V. Delgado-maroto, M. Pedreno, L. Martinez-escudero et al., Paradoxical Effect of Cortistatin Treatment and Its Deficiency on Experimental Autoimmune Encephalomyelitis, The Journal of Immunology, vol.191, issue.5, pp.2144-54, 2013.
DOI : 10.4049/jimmunol.1300384

D. Loh, C. Abad, C. Colwell, and J. Waschek, Vasoactive Intestinal Peptide Is Critical for Circadian Regulation of Glucocorticoids, Neuroendocrinology, vol.88, issue.4, pp.246-55, 2008.
DOI : 10.1159/000140676